Finance entity
Every one of those 2 sits in a single category, markets. AMT-130 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across a 48-day span, the pace is roughly 0.3 stories per week. Each story carries 2 original sources on average, compared with 3.1 for the broader beat in this window.
Last mentioned: Aug 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, markets. AMT-130 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across a 48-day span, the pace is roughly 0.3 stories per week. Each story carries 2 original sources on average, compared with 3.1 for the broader beat in this window. At 5.5, the average consequence score sits below the same-window beat average of 6.3. We currently track 2 Finance stories that mention uniQure, published between June 19, 2026 and August 5, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 804 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering uniQure. Shared-story counts are live from our verified record — not editorial picks.
A slate of upcoming catalysts could drive the next move for uniQure, CareDx, Adaptive Biotechnologies, Enliven Therapeutics, and Amylyx Pharmaceuticals, all of which posted big gains recently. uniQure's Q3 regulatory filing and September four-year data are key events.
From uniQure’s gene therapy rally to SLP’s buyout premium, biotech stocks are making big moves. Compliance wins and upcoming Q4 data add to the catalyst-rich environment for investors.
uniQure is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
